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Summary
The generation of an in vitro major histocompatibility complex class I specific response of
CD4-CD8 - T cell receptor (TCR) ctO cytotoxic T lymphocytes (CTL) and their allogeneic
tumor rejection were investigated. Inocula ofBALBRLo' 1 were rejected in C57BL/6 (B6) mice
treated with minimum essential medium (MEM) (control), anti-L3T4 (CD4) monoclonal antibody
(mAb) or anti-Lyt-2.2 (CD8) mAb and CTL against the tumor were generated in vitro. No
rejection and no induction of CTL were observed in B6 mice treated with anti-L3T4 (CD4)
plus anti-Lyt-2.2 (CD8) mAb. CTL with the classical Thy-1+CD3+CD4 - CD8+ TCR aß
phenotype were generated in mixed lymphocyte tumor cell culture (MLTC) spleen cells from
B6 mice treated with MEM (control) or anti-L3T4 (CD4) mAb, whereas CTL with an unusual
Thy-1+CD3+CD4 - CD8 - TCR aß phenotype were generated in MLTC spleen cells from
anti-Lyt-2.2 (CD8) mAb-treated B6 mice. Both types of CTL were reactive with both H-2Kd
and Dd (Ld) class I antigen. These findings suggest that when CD4+ cells were blocked by anti-
L3T4 (CD4) mAb, CD8+ CTL mediated rejection, and when CD8+ cells were blocked by
anti-Lyt-2.2 (CD8) mAb, CD4+ cells were capable of mediating rejection, although less
efficiently than CD8+ cells, by inducing CD4 - CD8- TCR aß CTL. The finding that adoptive
transfer of CD4 and CD8-depleted MLTC spleen cells, obtained from anti-Lyt-2.2 (CD8) mAb-
treated B6 mice that had rejected BALBRLa 1, resulted in rejection of BALBRLa 1 inoculated
into B6 nu/nu mice confirmed the above notion. CTL clones with the CD4 - CD8 - TCR aß
phenotype specific for Ld were established.
T
hymocytes with the CD4 - CD8- phenotype constitute
about 5% of all cells in the thymus of adult mice (1).
The TCR cxß-bearing subset constitutes 2-30% of the
CD4- CD8- thymocytes in different mouse strains and dis-
plays a CD3+, HSA - , CD5h'gh, IL2R- , Pgp-1+, B220 - ,
and Qa-2+ phenotype (2-6). Although these cells appear to
have a functional TCR (7), the origin and developmental
pathway of CD4 - CD8 - TCR aß cells is currently un-
known. Recently, however, it was shown that tolerance-related
Vß clonal deletion took place in CD4 - CD8 - TCR aß
thymocytes from mice with Mls' and Mlsr alleles and mice
expressing I-E (8). Clonal deletion has been shown to occur
at the stage of CD4+CD8+ thymocytes and to involve the
CD4 or CD8 molecule (9-11). These findings suggest that
CD4 - CD8' TCR aß thymocytes are formed at a late stage
of differentiation by down-regulationof CD4 and CD8 mol-
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ecules (1, 8). Alternatively, these cells could represent an in-
dependent lineage of T cells that never express CD4 and CD8
molecules during their differentiation.
Although appreciable numbers of CD4-CD8- TCR aß
cells are found in the thymus, these cells are rarely detected
in peripheral lymphoid tissues. However, CD4- CD8 - TCR
aß cells have been shown to accumulate in the lymph nodes
of autoimmune lpr (12-15) or gld (13, 16, 17) mice. The
CD4-CD8 - TCR a,ß cells in these mice also undergo Vß
clonal deletion (8, 18) and thymectomy prevents disease de-
velopment (19, 20). These findings suggest that CD4 -
CD8 - TCR aß cells in the lymph nodes of these mice are
derived from thymocytes with this phenotype. Recently, T
cells with this phenotype have been shown to be present in
the lymph nodes of normal mice (21).
In this paper, we report that a CD4 - CD8 - TCR aß
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antigen was generated in C57BL/6 (B6)1 mice that had been
treated with anti-Lyt-2.2 (CD8) mAb and had rejected the
BALBRLo 1 tumor, and that adoptive transfer ofthesecells
to B6 nu/nu mice resulted in rejection of the tumor.
Materials and Methods
Mice. A/J, BALB/c, C57BL/6 (B6), B10.A, B10.D2 and
C3H/He mice were purchased from Japan SLC Inc. (Shizuoka,
Japan). Breeding pairs of C3H.OH, B10.A (5R), B10.AQR and
B10.HTG mice were provided by Dr. K. Moriwaki (National In-
stitutes of Genetics, Mishima, Japan). Breeding pairs ofB6 nu/+
mice were provided by Dr. K. Kuribayashi (Faculty of Medicine,
KyotoUniversity, Kyoto, Japan). Breeding pairs of BALB.B mice
were provided by Dr. H.Fujiwara (OsakaUniversity MedicalSchool,
Osaka, Japan). These mice were bred in the Laboratory Animal
Center for Biomedical Research (Nagasaki University School of
Medicine, Nagasaki, Japan).
Tumor. BALBRLU 1 is a radiation-induced leukemia (22).
B6LK is anitrosomethylurea-induced thymic leukemia that expresses
TCR a/3, CD4, and CD8 on thecell surface. K4D11 is a T cell
lymphoma that developed in a C3H TgTla'-3-1 transgenic mouse
and expresses TCR -yb, but not CD4 or CD8, on the cell surface
(23). The tumors were maintained in the strain of origin.
Antibodies.
￿
Anti-L3T4 (CD4)mAb, a rat antibody of the IgG2b
immunoglobulin class, produced by hybridoma GK1.5 (24), was
provided by Dr. F. Fitch (University of Chicago, Chicago, IL).
Anti-Lyt-2.2 (CD8) mAb, a mouse antibody of the IgG2a class,
produced by hybridoma19/178 (25) wasprovidedby Dr. U. Ham-
merling (Memorial Sloan-Kettering Cancer Center, New York,
NY). Anti-TCRa mAb, a hamsterantibody of theIgG class, pro-
ducedby hybridoma H57-597 (26), wasprovided by Dr. R. Kubo
(NationalJewish Center, Denver, Co.) . Anti-TCR S mAb, a ham-
ster antibody ofthe IgG class, produced by hybridoma 3A10 (27)
was provided by Dr. S. Itohara (M.IT, Cambridge, MA). Anti-
CD3 mAb, a hamster antibody of the IgG class, produced by hy-
bridoma 145-2C11(28), wasprovidedby Dr. J.A. Bluestone (Univer-
sity ofChicago, Chicago, IL). Anti-thymus leukemia (TL) mAb's
were rat antibodies of the IgG2a and IgG2b classes produced by
hybridoma 168and177, respectively (29). Anti-Qa2mAbis amouse
IgM antibody produced by ahybridomaHDQa-2. Anti-Qa 3 mAb
is amouseIgG2a antibody produced by ahybridomaQa3-59. Anti-
H-2Kd mAbis a mouse IgG2a antibody produced by ahybridoma
HB159. Anti-H-2D' mAb is a mouse IgG2a antibody produced
by a hybridoma HB102(30). Both these mAbs were obtained from
the American Type Culture Collection (Rockville, MD). Anti-
H-2Ld mAb is a mouse IgG2a antibody produced by ahybridoma
30-5-7 (31). H-2d antibodies used are B6 anti-BALBRLa 1, B6
anti-BALB/c methylcholanthrene sarcomaMeth A(BALBMethA)
and B6 anti-BALB/c spleen cells.
Cytofluorometric Analysis. Cells (1-2 x 106) were incubated
with mAb for 30 min at 4°C. The following mAb's were used:
PE-conjugated anti-L3T4 (CD4) mAb (clone GK1.5), FITC-
conjugated anti-Lyt-2 (CD8) mAb (clone 53-6.7), and FITC-
conjugated anti Thy-1.2 mAb (clone 30-1112) were obtained from
Becton Dickinson&Co. (Mountain View, CA). Biotin-conjugated
1 Abbreviations used in this paper: B6, C57BL/6;bml, B6.C-H-2bmi;bm12,
B6.C-H-2bm1z; MGS, mean graft survival; MLTC, mixed lymphocyte
tumor cell culture; MMC, mitomycin C; TL, thymus leukemia.
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antiThy-1.2 mAb (25) andFITC-conjugated anti-CD3 mAb (145-
2C11) were provided by Dr. M. Kawai (Osaka University Medical
School, Osaka, Japan). Biotin-conjugated antiV06 mAb (44-22-
1) (32) and antiVs8 mAb (F23.1) (33) were provided by Dr. K.
Kuribayashi (Kyoto University, Kyoto, Japan). For unconjugated
anti-L3T4 (CD4) mAb and anti-Lyt-2.2 (CD8) mAb, FITC-
conjugated goat anti-rat IgGandFITC-conjugatedgoat anti-mouse
Ig(G+M) F(aV)zwere used, respectively, as second antibody. For
unconjugated anti TCR0mAb (1157-597), FITC-conjugated goat
anti-hamster IgGthat had been absorbed with mouse Ig (Caltag,
San Francisco, CA) was used as second antibody. PE-conjugated
streptavidin (BectonDickinson and Co.) was used forbiotinylated
mAb. After treatment, the cells were washed, suspended in PBS,
and analyzed in a FACScan (Becton Dickinson and Co.).
Generation ofConcanavalin A (Con A) Blast Cells.
￿
Spleen cells
(2 x 10') were cultured with Con A at a concentration of 5
ug/ml for 3 d.
In VitroSensitization of Spleen Cells.
￿
Mixedlymphocyte tumor
cell culture (MLTC) was performedby incubating responderspleen
cells (5 x 10') with 5 x 106 mitomycin C (MMC)-treated
BALBRLo' 1 cells. MMC treatment was done by incubating cells
with MMC at aconcentration of 100,ug/ml for 30 min at 37°C.
Theculturemedium wasRPMI 1640 supplemented with 10% heat-
inactivated FCS, 2 mM glutamine, 100U ofpenicillin per ml, 100
,ug of streptomycin per ml, and 50 AM 2-ME. MLTC cells were
harvested after 5 or 6 d culture and used as effector cells in assays
of cell-mediated cytotoxicity.
Pretreatment ofEffector Cellswith MAband Complement (C).
￿
Ali-
quots of MLTC cells (5 x 106) or cloned CTL (2 x 106) were
incubated with mAb (diluted 1:20 with MEM) in avolume of0.2
ml for 30 min at 4°C. The cells were then washed once and
resuspended in 0.75 ml of preselected rabbit serum (diluted 1:10
with MEM) as a source of C.Afterincubation for 30 minat 37°C,
the cells were washed three times before use.
Cell-mediatedCytotoxicity Assay.
￿
BALBRLO' 1 or Con Ablasts
were labeled with "Cr by incubating 5 x 106 cells with 2 MBq
of Na2CrO4 (New England Nuclear, Boston, MA) in 0.3 ml of
medium for 45 min at 37°C in an atmosphere of 5% CO2 in air.
Then the cells were washed twicewith culture medium and used
as target cells. In direct assays, 2 x 104 labeled target cells (100
jl) were incubated with the effector cell suspension (100 JAI). In
antibody blocking assays, serially diluted mAb or antiserum (50
P,1) was added to the culture of effector (50 IAl) and labeled RLu
1 target cells (2 x 104) (501A1) during assay. After incubation for
3 h at 37°C, the supernatants (100 Etl) were removed and their
radioactivity was measured in an Aloka ARC 300 y counter. The
percentage of specific lysis was calculated by the following equa-
tion: (a-b/c-b) x 100, where a is the radioactivity in thesuperna-
tant of target cells mixedwith effector cells, b is that in the super-
natant of target cells incubatedalone, andc is that in thesupernatant
after lysis of target cells with NP-40.
EstablishmentandMaintenance ofCytotoxic TLymphocyte Clones.
Limited numbers of MLTC cells were cultured with 5 x 105 ir-
radiated (2,000 tad) syngeneic spleen cells and 5 x 103 irradiated
(10,000 tad) tumor cells in a volume of 0.2 ml in 96-well flat-
bottomed microplates (Corning 25860; Corning Glass Works,
Corning, NY). After culture for 14 d, cell growth was assessed
microscopically and cytotoxicity wasmeasured usinghalf thecul-
ture (0.1 ml). Cells in wells that showed cytotoxicity were trans-
ferred to 24-well culture plates (Corning 25820; Corning Glass
Works) and maintained by culture with 5 x 106 irradiated (2,000
tad) syngeneic spleen cells and 5 x 104 irradiated (10,000 tad)
tumorcells in medium containing humanrecombinant IIr2 (TakedaPharmaceutical, Osaka, Japan) at aconcentration of0.1 U/ml. After
initial expansion, CTL were recloned and passaged every 5 d by
transferring 105 cells to new wells of multiwell plates.
Tumor Assay. BALBRLo' 1 cells were harvested in MEM
medium andwashed twice. The hair of theback ofmice was shaved
with animal clippers and the tumor cells (2 x 106) were injected
i.d. through a 27-gauge needle. Tumor diameters at right angles
were measured with vernier calipers to calculatethemean diameter.
Antibody Administration.
￿
Mice were anesthetized with etherand
200 I1 of antibodies (ascites diluted 1:8 with MEM) was injected
through the retrobulbar venous plexus.
We found previously by antibody-mediated complement-
dependent cytotoxicity assay that injections of anti-L3T4 (CD4)
mAbandanti-Lyt-2.2 (CD8) mAb resulted in the elimination from
the peripheral lymphoid tissues of CD4* cells and CD8' cells,
respectively (34). Blocking of the functions of CD4* cells and
CD8' cells in vivo by mAb treatment was monitored by skin
graftrejection in combinations of H-26 mutant strains and B6. A
single injection ofanti-L3T4 (CD4)mAbprolonged themean graft
survival (MGS) in B6 mice of B6.C-H-2bmlz (bm12) skin (MGS,
32.8 ± 12.1 d:MGS ofMEM-treated mice, 12.8 ± 1.2 d [p <0.05]),
but not of B6.C-H-2bml (bml) skin (MGS, 12.0 ± 1.0 d: MGS of
MEM-treated mice, 15.0 ± 0.9 d). On the otherhand, anti-Lyt-
2.2 (CD8) mAb prolonged the survival in B6 mice of bml skin
(28.4 ± 9.9 d [p < 0.05]), but not ofbm12 skin (12.2 ± 0.8 d).
In this study, to eliminate the CD4* or CD8* cells completely
during theexperiments, mAb's(25 P,1 ofascites) were administered
every 4 d until tumors regressed.
Adoptive Transfer. Either CD4, or CD4 and CD8-depleted
MLTC cells (6 x 106) were adoptively transferred to B6 nu/nu
mice 5 d before challenge of the mice with BALBRL0' I tumor
cells. To ensure depletion of CD4* cells, and of CD4' and CD8*
cells, the mice were treated with anti-L3T4(CD4) mAb, andboth
anti-L3T4 (CD4) andanti-Lyt-2.2 (CD8)mAb, respectively, during
tumor assay.
Northern BlotAnalysis.
￿
TotalRNA's from MLTC cells, cell lines,
and tumor cells were isolated by the guanidine thiocyanate/CsCl
procedure (35). Fractionated RNAwasblotted onto nitrocellulose
filters (Schleicher & Schuell, Keene, NH) and hybridized with
["P]dCTP-labeled probes in the presence of 50% formamide for
18 h at 45*C as described (36). Filters were washed and exposed
to X-rayfilm (XAR-5; Eastman Kodak, Rochester, NY). The fol-
lowing probes were used: pSP64L3T4 for L3T4 (CD4) (37)
(providedby Dr. D. R. Littman, University ofCalifornia, SanFran-
cisco, CA), pI .Y2C-1 forLyt-2(38) (providedbyDr. H. Nakauchi,
The Institute ofPhysical and Chemical Research, Tsukuba, Japan),
pclca for TCR a (39) (provided by Dr. T. W Mak, The Ontario
Cancer Institute, Toronto, Canada), PL5 forTCR /3 (provided by
Dr. D. Y Loh, Washington University School of Medicine, St.
Louis, MO), p8/10-2y 1.1 forTCR y(40) (providedby Dr. T W .
Mak), and RAD11C forTCR 6 (41) (providedby Dr. Y. Yoshikai,
Nagoya University School of Medicine, Nagoya, Japan).
Results
Effects ofIn Vivo Administration ofAnti-L3T4 (CD4)MAb
and, or Anti-Lyt-2.2 (CD8) MAb on Rejection ofBALBRLO'
1 by B6 Mice. Inocula of 2 x 106 BALBRLo' 1 cells in the
back of C57BL/6 (B6) mice grew to tumors with a max-
imum diameter of 7-11 mm on day6-7, which then regressed
anddisappeared by day 10-12. The effects of administration
of anti-L3T4 (CD4) mAb and, or anti-Lyt-2.2 (CD8) mAb
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Figure 1.
￿
Effects of in vivo administration o£ MEM(control) (A), anti-
L3T4 (CD4) mAb (B), anti-Lyt-2.2 (CD8) mAb (C) and a combination
o£ both (D) on rejection of BALBRLO' 1 by B6 mice. Inocula of 2 x
106 BALBRLO' 1 cells were injected i.d., into the back of recipients.
Volumes of0.2 ml ofmAb(ascites) (diluted 1:8 with MEM) wereinjected
i.v. every 4 d.
to recipient mice on growth of tumors were investigated.
As shown in Fig. 1, administration of either MEM (control),
anti-L3T4 (CD4) mAb or anti-Lyt-2.2 (CD8) mAbresulted
in rejection, although significant delaywas observed in mice
treated with anti-Lyt-2.2 (CD8) mAb. Administration ofboth
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Figure 2.
￿
Generation and phenotypic analysis of CTL. Spleen cells (5
x 107) from B6 mice treated with MEM (control) (A), anti-L3T4 (CD4)
mAb (B), anti-Lyt-2.2 (CD8) mAb (C) or a combination of both (D)
obtained 7dafterrejection (A-q or 12dafter inoculation (D)ofBALBRLO'
1 tumor were cultured with 5 x 106 MMC-treated BALBRLO' 1 in a
volume of 20 ml for 6 d. BALBRLO' 1 cytotoxicity on MLTC cells was
tested by a 3-h chromium assay. The CTL phenotype was determined by
elimination ofcytotoxicity by pretreatment with mAbandCbefore assay.
(x) antiThy-1.2 mAb; (0) anti-L3T4 (CD4) mAb; (p) anti-Lyt-2.2
(CD8) mAb; (") anti-L3T4 (CD4) mAb and anti-Lyt-2.2 (CD8)mAb;
(A) C alone; (O) untreated.anti-L3T4 (CD4) mAb and anti-Lyt-2.2 (CD8)mAb blocked
rejection.
In Vitro Cytotoxic T Lymphocyte Responses of Spleen Cells
from MEM(Control), Anti-L3T4 (CD4)MA 4 or Anti-Lyt-2.2
(CD8)MAb-Treated B6 Mice that Rejected BALBRLa1. CTL
were generated by in vitro stimulation with mitomycin C
(MMC)-treated BALBRLO' 1 cells of spleen cells from B6
mice treated with MEM (control), anti-L3T4 (CD4) mAb
or anti-Lyt-2.2 (CD8) mAb that had rejected theBALBRLO'
1 tumor, but not on similar treatment of spleen cells from
B6 mice treated with both mAbs and bearing BALBRLO'
1 tumor (9-13 mm diameter) obtained 12 d aftei tumor in-
oculation (Fig. 2) . Thecytotoxicity generatedin MLTC spleen
cellsfrom B6 mice treated with MEM (control) or anti-L3T4
(CD4) mAb was abolished by treatment with antiThy-1.2
mAb or anti-Lyt-2.2 (CD8) mAb, but not with anti-L3T4
(CD4) mAb and complement (C). On the other hand, the
cytotoxicity generated in MLTC spleen cells from anti-Lyt-
2.2 (CD8) mAb-treated B6 mice was abolished by treatment
with anti Thy-1.2 mAb, butnot with anti-L3T4 (CD4) mAb
or anti-Lyt-2.2 (CD8) mAb and C.
Specificity Analysis and Antibody Blocking of CTL.
￿
The
CD4-CD8+ CTL generated in MLTC spleen cells from
MEM (control) or anti-L3T4 (CD4) mAb-treated B6 mice
that had rejected BALBRLO' 1 and the CD4-CD8- CTL
generatedin MLTC spleen cellsfrom anti-Lyt-2.2 (CD8) mAb-
treated B6 mice that had rejected BALBRLO' 1 showed similar
specificities: these CTL lysed target cells that expressed ei-
ther H-2Kd or H-2Dd (Ld) antigen (Fig. 3). Next we exam-
ined the blocking of CTL with antibody. CD4-CD8+
CTL were blocked by anti-CD3 mAb, antiTCR a mAb,
anti-Lyt-2.2 (CD8) mAb or anti-H-2d serum, but not by
anti-L3T4 (CD4) mAb, as shownby additionsof these anti-
bodies to cultures during assays (Fig. 4 A). On the other
hand, CD4-CD8- CTL were blocked by anti-CD3 mAb,
100 A
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￿
Comparison of specificities of CD4 - CD8* CTL generated
in MLTC spleen cells of B6 mice treated with anti-L3T4 (CD4) mAb that
had rejected BALBRLa' 1 (A) and CD4-CD8 - CTL generated in MLTC
spleen cells of B6 mice treated with anti-Lyt-2.2 (CD8) mAb that had
rejected BALBRDY 1 (B). Con A stimulated spleen cells were used as
target cells. (") B6 (KbDb); (") BALB/c (KdDdLd); (p) BALRB (KbDb).
(") C3H/He (KkDk); (A) C3H.OH (KdDk); (") A/J (KkDdLd); (x)
B10M (KdDdLd); (p) B10.HTG (KdDb); (O) B10.A (KkDdLd).
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￿
Antibody blocking ofCD4 - CD8 * CTL generated in MLTC
spleen cells from anti-L3T4 (CD4) mAb-treated B6 mice that had rejected
BALBRLo' 1 (A) and CD4-CD8 - CTL generated in MLTC spleen cells
from anti-Lyt-2.2 (CD8) mAb-treated B6 mice that had rejectedBALBRLa'
1 (B). (O) anti-L3T4 (CD4) mAb; (") anti-Lyt-2.2 (CD8) mAb; (p)
antiTCR (3 mAb (H57-597); (0) anti-TL mAb (168); (C) anti-TL mAb
(177); (A) anti-Qa-2 mAb; (") anti-Qa-3 mAb; (x) anti-CD3 mAb
(145-2CH); (A) conventional anti-H-2d serum; (®) none. The effector to
target cell ratio was 2.5:1 in A and 7.5:1 in B.
anti TCRa mAb or anti-H-2d serum, but not by anti-L3T4
(CD4) mAb or anti-Lyt-2 .2 (CD8) mAb (Fig. 4 B). Anti-
H-2d serum used in these experiments include B6 anti-
BALBRLO' 1, B6 anti-BALBMeth A and B6 anti-BALB/c
spleen cells and.the effect wasessentially similar. No blocking
of either type of CTL was observed with the antiTL mAb,
anti-Qa-2 mAb, or anti-Qa-3 mAb.
Cytofluorometric Analysis.
￿
Cytofluorometric analysis showed
that in vivo administration of anti-L3T4 (CD4) mAb and
anti-Lyt-2 .2 (CD8) mAb resulted in depletion of CD4+ and
CD8+ cells, respectively, in peripheral lymphoid tissues.
Depletion of CD4+ cells in spleen and lymph node cells was
shownby alack ofcellsthat stained with PE anti-L3T4 (CD4)
mAb, and by a lack of Thy-1+ cells that would double label
with either FITC anti-rat Ig or anti-L3T4 (CD4) mAbplus
FITC anti-rat Ig. Similarly, depletion of CD8+ cells was
evident by alack ofcellsthat stainedwith FITC rat anti-Lyt-2
(CD8) mAb, and by a lack of Thy-1+ cells that would
double label with either FITC anti-mouse Ig or anti-Lyt-
2.2 (CD8) mAb plus FITC anti-mouse Ig.
The populations of CD4+ and CD8+ cells in 6-d cultures
of MLTC spleen cells from MEM (control)-treated B6 mice
that had rejected BALBRLO' 1 were approximately 20 and
70%, respectively, of the total cells (Fig. 5 A). Scarcely any
CD4+ or CD8+ cells were detected in cultures of MLTC
spleen cellsfrom B6 mice treated with anti-L3T4(CD4)mAb
or anti-Lyt-2.2 (CD8) mAb that had rejected BALBRLO'
1 (Fig. 5, B andC). Since thecytotoxicity generatedin MLTC
spleen cells from anti-Lyt-2.2 (CD8) mAb-treated B6 mice
that had rejected BALBRLO' 1 resided mainly in cells with
the unusual Thy-1+ CD4-CD8- phenotype, as described
above, TCRexpression in this cell population was examined.
MLTC spleen cells from anti-Lyt-2.2 (CD8) mAb-treatedB6
mice were depleted of both CD4+ and CD8+ cells by mAbFigure 5 .
￿
Cytoliuorometric analysis. Spleen cells (5 x 107 ) fromMEM
(control) (A), anti-L3T4 (CD4) mAb (B) or anti-Lyt-2 .2 (CD8) mAb
(C)-treated B6 mice that had rejected BALBRL(7 1 were cultured with
5 x 106 cells of MMC-treated BALBRLO' 1 in a volume of 20 ml for
6 d . MLTC cells were stained with PE anti-L3T4 (CD4) mAb and FITC
anti-Lyt-2 (CD8) mAb. MLTC cells in (C) were treated with anti-L3T4
(CD4) mAb and anti-Lyt-2.2 (CD8) mAb and C, and stained with PE
anti-L3T4 (CD4)mAb and FITC anti-Lyt-2 (CD8) mAb (D), biotinylated
anti Thy-1.2mAb with PE-avidin and FITC anti-CD3 mAb (145-2C11)
(E) or antiTCR 0mAb (H57-597) (F) with FITC anti-hamster IgG, bio-
tinylated antiVß6 mAb (G) or antiVß8 mAb (H) with PE avidin and
FITC antiThy-1.2 mAb. (~ PE avidin alone.
and C (Fig. 5 D) . Thy-1+ CD3+ cells constituted about
70-80% of the total CD4 -CD8 - cells in MLTC (Fig. 5 E),
and most of these were TCR aß-positive cells (Fig. 5 F) .
TCR Vß6- and Vß8-positive cells constituted -0% and
x+20% of the Thy-1 positive cells, respectively (Fig. 5, G
and H) .
Rejection ofBALBRLOF 1 Inoculated intoB6 nu/nu Mice by
Adoptive Transfer ofCD4-CD8 - Cells Obtained from Anti-
Lyt-2.2 (CD8) MAb-Treated B6 Mice that Had Rejected
BALBRLo' 1 . MLTC spleen cells from anti-L3T4 (CD4)
mAb-treated B6 mice that had rejected BALBRLU 1 were
treated with anti-L3T4 (CD4) mAb and C, and 6 x 106
cells were adoptively transferred to B6 nu/nu mice 5 d before
challenge of the mice with BALBRLO' 1 tumor. In these
mice, BALBRLU 1 grew to a tumor, and then regressed
(Fig . 6 A) . For examination of the in vivo effector activity
of Thy-1+ CD4 -CD8 - CTL, MLTC spleen cells from
anti-Lyt-2.2 (CD8) mAb-treated B6 mice that had rejected
BALBRLO' 1 were treated with both anti-L3T4 (CD4) mAb
and anti-Lyt-2.2 (CD8) mAb and C, and the same number
of cells were similarly transferred to B6 nu/nu mice. To re-
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￿
Adoptive transfer experiments . B6 nu/nu mice were injected
i.p. with 6 x 106MLTC spleen cells from anti-L3T4 (CD4) mAb-treated
B6 mice that had rejected BALBRLO 1, which were depleted of L3T4
(CD4)* cells (A and B), and from anti-Lyt-2 .2 (CD8) mAb-treated B6
mice that had rejected BALBRLcr 1, which were depleted ofboth L3T4
(CD4)" and Lyt-2 .2 (CD8) * cells (C and D), 5 d before challenge with
BALBRLcr 1 tumor. Anti-L3T4 (CD4) mAb (A and B), and a combina-
tion of both anti-L3T4 (CD4) and anti-Lyt-2 .2 (CD8) mAb (C and D)
were administered to recipient B6 nuAu mice to ensure depletion on days
-5, 0, 10, 20, and 30. Anti-Lyt-2.2 (CD8)mAb (B) or antiTCR0mAb
(H57-597) (D) was administered on days 0, 10, 20, and 30 .
Figure 7 .
￿
Spleen cells (5 x 107) from B6 nuAw mice that had received
adoptive transfer ofCD4-CD8- cells (shown in Fig . 6 C) were obtained
7 d after rejection of BALBRLU 1 and were cultured with 5 x 10 6
MMC-treated BALBRLa' 1 in a volume of 20 ml for 6 d . BALBRLo'
1 cytotoxicity was tested by a 3-h chromium assay. TheCTL phenotype
was determined by pretreatment with mAb and C before assay (A) . (x)
antiThy-1 .2 mAb ; ((]) anti-L3T4 (CD4) mAb ; (p) anti-Lyt-2 .2 (CD8)
mAb ; (" ) anti-L3T4 (CD4) mAb and anti-Lyt-2 .2 (CD8)mAb; (A)C
alone; (O) no treatment . MLTC cells were depleted ofL3T4 (CD4)' and
Lyt-2 .2 (CD8) * cells by treatment with mAb and C, and stained with
PE anti-L3T4 (CD4)mAb and FITC anti-Lyt-2 (CD8)mAb (B) and anti
TCR 0mAb (H57-597)
￿
antiTCR 6 mAb (3A10) ( . . . . . . ) or anti-
CD3 mAb (145-2C11) (
￿
" " ) with FITC anti-hamster IgG (C) .
(---) FITC anti-hamster IgG alone .60
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Figure 8.
￿
Elimination (A), direct cytotoxicity (B), antibody blocking
(C), and cytofluorometric analysis (D) of CTL clone S 1. In A, S 1 cells
were pretreated with mAb's and C before cytotoxicity assay. The target
cells were BALBRLo" 1. (x) antiThy-1.2 mAb; (p) anti-L3T4 (CD4)
mAb; (p) anti-Lyt-2.2 (CD8) mAb; (") anti-L3T4 (CD4) mAb and
anti-Lyt-2.2 (CD8) mAb; (A) C alone; (O) untreated. In B, Con A stimu-
lated spleen cells were used as target cells. (") B6 (KbDb); (/) BALB/c
(KdDdLd); (A) C3H.OH (KdDk); (17) B10.HTG (KdDb); (O) B10.A (5R)
(KbDdLd); (") B10.AQR (KgDdLd). In C, the antibodies used for
blocking were (O) anti-L3T4 (CD4) mAb; (") anti-Lyt-2.2 (CD8) mAb;
(0) antiTCR /3 mAb (H57-597); (A) anti-H-2Kd mAb (HB159); (")
anti-H-213d mAb (HB102); (/) anti-H-2Ld mAb (30-5-7); (x) anti-CD3
mAb (145-2C11); and (A) conventional anti-H-2d serum. (O) none. The
effector to target cell ratio was 1:1. In D, Sl cells were stained with PE
anti-L3T4 (CD4) mAb and FITC anti-Lyt-2 (CD8) mAb.
duce the possibility of involvement of CD4+ and CD8+
cells that escaped from depletion and proliferated, we added
both anti-L3T4 (CD4) mAb and anti-Lyt-2.2 (CD8) mAb
during tumor assay. Adoptive transfer of CD4- CDS - cells
resulted in rejection of BALBRLO' 1 tumors, although less
efficiently than adoptive transfer of a CD4 - CD8+ popula-
tion (Fig. 6 C). Administration of anti TCR 0 mAb (H57-
597) abolished rejection by the CD4 -CD8 - population,
confirming the TCR aR phenotype of the effector cells (Fig.
6 D). Administration of anti-L3T4 (CD4) mAb and/or
anti-Lyt-2.2 (CD8) mAb, or antiTCR /3 mAb (H57-597)
alone had no effect on BALBRLO" 1 tumor growth in B6
nulnu mice. Thy-1+ CD4-CD8 - CTL were recovered from
MLTC spleen cells of B6 nulnu mice that had rejected
198 CD4 -CD8- T Cell Receptor a,8 Cytotoxic T Lymphocyte
BALBRLoa 1 after adoptive transfer of a CD4 - CD8 -
population (Fig. 7).
Establishment of CD4 - CD8- TCR a(3 CTL Clones.
MLTC spleen cells from anti-Lyt-2.2 (CD8) mAb-treated B6
mice that had rejected BALBRLO' 1 were treated with anti-
L3T4 (CD4) mAb plus anti-Lyt-2.2 (CD8) mAb and C. The
residual cells were plated at 1 cell/well in 96-well plates and
cultured with irradiated BALBRLa 1 and B6 spleen cells.
In this way, CTL clones S 1 and 2 were obtained from in-
dividual mice. Both these clones were found to be Thy-
1+CD4-CD8 - TCRa#+Vs6 - VO8 - by cytofluorometry
and were specific for Ld (Fig. 8) .
Northern Blot Analysis.
￿
The expression of L3T4 (CD4),
Lyt-2 (CD8) and TCR genes in the MLTC spleen cells and
the CTL clones S 1 and 2 were analyzed by Northern blot-
ting. Transcripts of the L3T4 (CD4) and Lyt-2 (CD8) genes
were detected in MLTC spleen cells from MEM-treated B6
mice that had rejected RLO' 1, but no transcripts of the Lyt-
2 (CD8) gene were detected in MLTC spleen cells from
anti-Lyt-2.2 (CD8) mAb-treated B6 mice that had rejected
BALBRLO' 1 (Fig. 9) . Transcripts of the TCR a, a, and
y genes, but not of the TCR S, L3T4 (CD4) or Lyt-2 (CD8)
genes, were detected in both S1 and 2 clones.
Discussion
In the present study, we demonstrated that MHC class
I specific CD4 - CD8 - TCR ao CTL were generated in
MLTC spleen cells from anti-Lyt-2.2 (CD8) mAb-treated B6
mice obtained after rejection of allogeneic BALBRLo° 1.
CD4 - CD8 - CTL were involved in mediating rejection of
the tumor in these mice.
Inocula of BALBRLO' 1 were rejected in B6 mice treated
with MEM (control), anti-L3T4 (CD4) mAb or anti-Lyt-
2.2 (CD8) mAb and CTL against the tumor were generated
in vitro. No rejection and no induction of CTL were ob-
served in B6 mice treated with both anti-L3T4 (CD4)
mAb and anti-Lyt-2.2 (CD8) mAb. CTL with the classical
Thy-1 + CD3 'CD4 - CD8 + phenotype was generated in
MLTC spleen cells from B6 mice treated with MEM (con-
trol) or anti-L3T4 (CD4) mAb, whereas CTL with an un-
usual Thy-1+CD3+CD4 - CD8 - phenotype were generated
in MLTC spleen cells from anti-Lyt-2.2 (CD8) mAb-treated
B6 mice. The CD4 - CD8 - phenotype of CTL was shown
by elimination and blocking of cytotoxicity. Pretreatment of
MLTC cells with antiThy-1 mAb, but not anti-L3T4 (CD4)
mAb or anti-Lyt-2 (CD8) mAb and C abolished the cyto-
toxicity. Addition of anti-CD3 mAb, but not anti-L3T4
(CD4) mAb or anti-Lyt-2.2 (CD8) mAb blocked the cyto-
toxicity in the absence of added C. No difference was ob-
served in the specificities of bulk CTL with the CD4-
CD8+ and CD4 - CD8 - phenotypes: both were reactive
with either H-2Kd or Dd (L'). These findings suggest that
when CD4+ cells were blocked by anti-L3T4 (CD4) mAb,
CD8+ CTL mediated rejection efficiently, and when CD8+
cells were blocked by anti-Lyt-2.2 (CD8) mAb, CD4+ cells
were capable ofmediating rejection, although less efficiently
than CD8+ cells, by inducing CD4-CDS - CTL.The CD4-CD8 - CTL demonstrated in this study use
TCR a(3 but not -yb . AntiTCR a mAb (H57-597) blocked
the in vitro cytotoxicity of CD4-CD8 - CTL and tumor
rejection in anti-Lyt-2.2 (CD8) mAb-treated B6 mice (data
not shown) or B6 nu/nu mice after adoptive transfer of
CD4-CD8 - CTL . Cytofluorometric analysis revealed that
Thy-1+ cells from anti-Lyt-2.2 (CD8) mAb-treated B6 mice
contained approximately 70-80% ofCD4- and CD8-depleted
MLTC cells and that most of the cells were TCR ao-positive.
V06- and V08-positive cells constituted 'ti0% and -20%
of the Thy-1+ cells, their levels being similar to those in
normal B6 thymorytes (42) . The CTL clones S 1 and 2 with
the Thy-1+CD3+CD4 -CD8' TCR ciO phenotype were
established from these MLTC cells .
The thymus was found to contain less than 1% ofT cells
with the CD4-CD8- TCR oiO phenotype (1) . The finding
that these cells respond to various stimuli and produce IL-2
(7) suggests that thymorytes with the CD4 -CD8 -TCR
cig phenotype are mature. Furthermore, clonal deletion has
been shown to occur in these cells (8, 18) . Although thymo-
rytes with this phenotype have been defined, no counterpart
has been detected in the peripheral lymphoid tissues of normal
mice . However, Guidos et al . (21) recently demonstrated that
V08+ cells are present in a CD3+CD4-CD8 - population
of lymph node cells . The present study demonstrated that
CD4'CD8' TCR cio T cells could be functionally in-
volved in immune responses . The in vivo administration of
anti-L3T4 (CD4) mAb with anti-Lyt-2.2 (CD8) mAb abol-
ished both BALBRLo 1 rejection and the in vitro CTL re-
sponse. These findings indicate that CD4+ cells were re-
quired for generation of the CD4 -CD8- TCR oca T cell
response, probably as helper cells. The effector cell mecha-
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Figure 9 .
￿
Northern blot analysis. mRNAs
were obtained from MLTC spleen cells from
MEM (control)-treated B6 mice that had re-
jected BALBRLcr 1 (A), MLTC spleen cells
from anti-Lyt-2 .2 (CD8) mAb-treated B6 mice
that had rejected BALBRLo" 1 (B), clone S 1
cells (C), clone S 2 cells (D), B6LK leukemia
cells (TCR a/3 CD4+CD8+) (E) and K4D11
leukemia cells (TCR -y6 CD4-CD8 - ) (F) .
The DNA probes used were pSP64L3T4 for
L3T4 (CD4), pLy2C-1 for Lyt-2 (CD8), pclca
forTCR a, PL5 forTCR 0, p8/10-2,y1 .1 for
TCR y, and RAD11C for TCR 6.
nisms of allograft or tumor rejection mediated by CD4+
cells are unknown (43, 44) . One possible mechanism could
be CD4-dependent induction of CD4-CD8- TCR a/3
effector cells. In this regard, it is noteworthy that the accumu-
lation of CD4 -CD8 - as cells observed in certain autoim-
mune mice has been shown to be dependent on CD4+ cells.
Treatment of MRTrlpr/lpr mice with anti-L3T4 (CD4) mAb
prevented accumulation of CD4 -CD8' TCR a)3 T cells
and the development of autoimmune disease (45) . This finding
suggests that CD4-CD8' TCR cio cells that are normally
present in these mice are somehow stimulated to proliferate
by activation ofCD4+ cells. The fact that CD4-CD8 - cells
in enlarged lymph nodes undergo clonal deletion suggests
that these cells are derived from normal counterparts in the
thymus (8, 18) . Class I specificCD4-CD8' a/3 CTL clones
have been generated from lymph node cells fromgld mice (46) .
CD4 -CD8 - effector cells were less efficient than
CD4- CI18+ effector cells in mediating tumor rejection .
Significant delay of BALBRLO" 1 tumor rejection was ob-
served in anti-Lyt-2.2 (CD8) mAb-treated B6 mice compared
with that inMEM (control) or anti-L3T4 (CD4) mAb-treated
B6 mice, and also in B6 nu/nu mice after adoptive transfer
ofCD4 and CD8-depleted MLTC spleen cells obtained from
anti-Lyt-2.2 (CD8) mAb-treated B6 mice that had rejected
BALBRLO' 1 compared with that in mice after adoptive
transfer of CD4-depleted MLTC spleen cells obtained from
anti-L3T4 (CD4) mAb-treated B6 mice . The exact reason
for the difference between the efficiencies of CD4-CD8-
and CD4-CD8+ cells is unknown. CD4-CD8 - effector
cells could be less efficient than CD4 -CD8+ effector cells .
Alternatively, the difference could be due to a lower number
of CD4 -CD8 - TCR aR CTL precursors.CD4-CD8+ effector cells were stimulated predominantly
and no significant involvement of CD4-CD8- cag CTL
was observed in MEM (control)-treated mice. Preferential stim-
ulation of CD4-CD8+ effector cells could be explained by
supposing that MHC class I antigen expressed on the
BALBRLa 1 tumor stimulated CD4-CD8+ a(3 CTL pref-
erentially to CD4-CD8- a/3 CTL, although the same an-
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